Leerink raises target for McKesson stock from USD 1,030 to USD 1,070

Published on 10/19/2026 at 09:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

McKesson stock trades at EUR 898.40 on October 19, 2026, 0.51 percent above its Xetra close. Q1 revenue reached USD 105.38 billion.

Analyst and transaction timeline

Leerink Partners lifted its McKesson target to USD 1,070.00 on October 7, 2026.
McKesson committed USD 1.40 billion to a minority stake in Option Care Health on October 6, 2026.
McKesson stock trades at EUR 898.40 at 9:24 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.51 percent above the Xetra close of October 16, 2026.
McKesson will publish second-quarter fiscal 2027 results on November 4, 2026.

Schwarzweißfoto eines Lagerarbeiters mit Wagen voller Kartons in großer Lagerhalle — Schwarzweiß-Reportagefoto dokumentiert McKesson Corporation ISIN US58155Q1031 im täglichen Logistikbetrieb mit Arbeiter im Pharma-Vertriebslager, Illustration mit AI erstellt.

McKesson (ISIN US58155Q1031) is supported by a higher Leerink Partners target of USD 1,070.00, up from USD 1,030.00 in a research note dated October 7, 2026, according to MarketBeat. The company is also pursuing a USD 1.40 billion minority investment in Option Care Health.

Leerink lifts the target

The Leerink change leaves the new target above McKesson's EUR 898.40 Lang & Schwarz price only as a cross-currency reference, so no euro upside calculation is applied. MarketBeat reported that 15 analysts rated the stock Buy and four rated it Hold on October 15, 2026, with a USD 983.29 average target.

What does the deal add?

McKesson said on October 6, 2026, that it would invest USD 1.40 billion for about 49 percent of Option Care Health, alongside CD&R. The transaction carries an enterprise value of USD 5.80 billion, and closing is expected in the first half of 2027, subject to approvals.

The strategic logic is specialty care. McKesson said Option Care's home and ambulatory infusion network fits its effort to expand access to complex therapies in lower-cost community settings. The investment adds a transaction milestone to the company's latest operating picture.

Three dated developments

On August 5, 2026, McKesson reported fiscal first-quarter revenue of USD 105.38 billion and adjusted earnings of USD 9.93 per share, versus USD 9.56 expected, according to MarketBeat. On October 1, 2026, the company reaffirmed fiscal 2027 adjusted earnings guidance of USD 44.20 to USD 45.00 while extending its CVS Health distribution agreement through June 2032, as Business Wire reported. On October 6, 2026, McKesson signed the Option Care agreement.

Dates for the next milestones

Business Wire identifies November 4, 2026, as the date for McKesson's second-quarter fiscal 2027 results and earnings call. The Option Care transaction is expected to close in the first half of 2027.

Stock stays above the Xetra close

McKesson stock was trading at EUR 898.40 at Lang & Schwarz on October 19, 2026, at 9:24 a.m. CEST, up EUR 4.60, or 0.51 percent, versus the Xetra close of October 16, 2026 at EUR 893.80. The quote was in pre-market trading under the Xetra session model. The further course of trading is shown by the continuously updated real-time quote of McKesson stock.